CN108883179A - 组蛋白脱乙酰酶抑制剂用于增强免疫治疗的用途 - Google Patents

组蛋白脱乙酰酶抑制剂用于增强免疫治疗的用途 Download PDF

Info

Publication number
CN108883179A
CN108883179A CN201780020460.2A CN201780020460A CN108883179A CN 108883179 A CN108883179 A CN 108883179A CN 201780020460 A CN201780020460 A CN 201780020460A CN 108883179 A CN108883179 A CN 108883179A
Authority
CN
China
Prior art keywords
entinostat
phenyl
methyl
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780020460.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·皮利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of CN108883179A publication Critical patent/CN108883179A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201780020460.2A 2016-01-28 2017-01-27 组蛋白脱乙酰酶抑制剂用于增强免疫治疗的用途 Pending CN108883179A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288121P 2016-01-28 2016-01-28
US62/288,121 2016-01-28
PCT/US2017/015389 WO2017132536A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Publications (1)

Publication Number Publication Date
CN108883179A true CN108883179A (zh) 2018-11-23

Family

ID=58010402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780020460.2A Pending CN108883179A (zh) 2016-01-28 2017-01-27 组蛋白脱乙酰酶抑制剂用于增强免疫治疗的用途

Country Status (13)

Country Link
US (1) US10813919B2 (https=)
EP (1) EP3407913A1 (https=)
JP (1) JP2019503386A (https=)
KR (1) KR20180104122A (https=)
CN (1) CN108883179A (https=)
AU (1) AU2017211383A1 (https=)
BR (1) BR112018015291A2 (https=)
CA (1) CA3013047A1 (https=)
IL (1) IL260765A (https=)
MX (1) MX2018009247A (https=)
RU (1) RU2018130831A (https=)
WO (1) WO2017132536A1 (https=)
ZA (1) ZA201805066B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569360A (zh) * 2019-09-30 2021-03-30 中国医学科学院药物研究所 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
IL264068B2 (en) * 2018-01-05 2023-07-01 Great Novel Therapeutics Biotech & Medicals Corp Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells
CN111836636A (zh) * 2018-01-12 2020-10-27 维拉克塔治疗公司 用于细胞免疫疗法的表观遗传修饰剂
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
EP4705341A1 (en) * 2023-05-05 2026-03-11 Euro-Celtique S.A. Combinations for treating cancer
WO2024238811A2 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same
US12553903B2 (en) 2023-06-01 2026-02-17 Cg Pharmaceuticals, Inc Ivaltinostat combination therapy for treating pancreatic cancer
WO2025155922A1 (en) * 2024-01-19 2025-07-24 The Trustees Of Indiana University Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
US9987258B2 (en) 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
ES2986548T3 (es) * 2015-03-20 2024-11-11 Syndax Pharmaceuticals Inc Combinación de inhibidor de HDAC y anticuerpo anti-PD-1 para el tratamiento del cáncer, en donde la combinación no comprende 5-azacitidina
US20180250320A1 (en) 2015-08-26 2018-09-06 The Johns Hopkins University Compositions and methods for treating solid tumors
BR112018003238A2 (en) * 2015-09-02 2018-09-25 Syndax Pharmaceuticals, Inc. patient selection for combination therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569360A (zh) * 2019-09-30 2021-03-30 中国医学科学院药物研究所 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用

Also Published As

Publication number Publication date
MX2018009247A (es) 2019-03-11
IL260765A (en) 2018-10-31
US20190030011A1 (en) 2019-01-31
WO2017132536A1 (en) 2017-08-03
US10813919B2 (en) 2020-10-27
JP2019503386A (ja) 2019-02-07
CA3013047A1 (en) 2017-08-03
EP3407913A1 (en) 2018-12-05
RU2018130831A (ru) 2020-03-02
AU2017211383A1 (en) 2018-08-16
RU2018130831A3 (https=) 2020-04-23
BR112018015291A2 (pt) 2018-12-18
KR20180104122A (ko) 2018-09-19
ZA201805066B (en) 2019-05-29

Similar Documents

Publication Publication Date Title
US10813919B2 (en) Use of histone deacetylase inhibitors for enhancing immunotherapies
JP6377632B2 (ja) 幹細胞の免疫制御作用を調節する方法
Li et al. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth
CN114286681A (zh) Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂
Yin et al. Topical treatment of all‐trans retinoic acid inhibits murine melanoma partly by promoting CD8+ T‐cell immunity
Zhou et al. Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity
Wang et al. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice
Jie et al. Retinoic acid regulates immune responses by promoting IL-22 and modulating S100 proteins in viral hepatitis
JP7235259B2 (ja) Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
JP2023027220A (ja) Ｈｄａｃ阻害剤とｂｅｔ阻害剤の使用方法及びその薬学的組み合わせ
Tanwar et al. Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE
Wu et al. Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy
Zhao et al. From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
WO2018224614A1 (en) Vegf inhibitors for use for preventing and/or treating acne
US20230158112A1 (en) Targeting gamma-delta T Cells in Obesity and Cachexia
CN104138391B (zh) 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用
US20240366954A1 (en) Compositions, systems, and methods for treating cancer using tumor treating fields and killer cells
Liang et al. Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment
US20250011781A1 (en) Methods and compositions targeting nucleus accumbens-associated protein-1 for treatment of autoimmune disorders and cancers
Fang et al. The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8+ CD103+ cDC1 and tissue-resident memory T cell responses
Wagner The Band Aide of the Broken Heart: The Immunomodulatory Properties of Cortical Bone Derived Stem Cells Post Ischemic Injury
US20250223555A1 (en) Reprogramming of immune-enhancing neutrophils by subclinical low-dose endotoxin for the treatment of cancer
Hayfani et al. Challenges in Approaching Management of Pulmonary Fibrosis
CN120661655A (zh) CpG岛结合蛋白KDM2B抑制剂的制药用途
Macciò¹ et al. Inflammation and Ovarian Cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123